Structure Therapeutics Inc.GPCR stock score: 29/100
$17.12 · -1.38% · Scored Nov 19, 2026
- Technical
- 20
- Fundamental
- 31
- News
- 52
The reading
Structure Therapeutics (GPCR) scores 29 out of 100, which reads bearish, higher than 3% of Healthcare stocks and 4% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 31, technicals 20.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Growth (Annual) at 1 weighs the most against it.
On the daily chart, trend-following indicators average 11 and contrarian oscillators 69 — a split worth reading before trusting the technical total.
News sentiment is neutral at 52; it is shown, not counted in the composite.
Since Aug 22, 2026 the composite has ranged from 28 to 47, and it is down 15 points over the period.
About Structure Therapeutics
Structure Therapeutics (GPCR) is a clinical-stage biopharmaceutical company that designs oral small-molecule drugs aimed at G-protein-coupled receptors, a large family of drug targets. It uses structural biology and computational chemistry to design pills that act on receptors usually targeted by injected peptide drugs. Its lead candidate, aleniglipron, is a once-daily oral GLP-1 receptor agonist for obesity, which produced meaningful weight loss in mid-stage trials and is moving into late-stage studies. Because it is a small molecule rather than a peptide, it may be cheaper to produce at large scale and does not need injections or fasting rules. The company is also developing oral amylin receptor agonists and other metabolic candidates. Structure has operations in South San Francisco and Shanghai, has no product revenue and funds research with cash raised from investors.
Structure competes with Eli Lilly and Novo Nordisk, which sell injectable obesity drugs and are developing or selling oral options, and with Roche, AstraZeneca, Viking Therapeutics and other developers of oral weight-loss drugs. Its edge rests on structure-based drug design, a small-molecule approach suited to mass production and data showing weight loss comparable with some injectable drugs. Investors who follow GPCR stock tend to watch the start and progress of late-stage aleniglipron trials. Tolerability findings, partnering interest and data from amylin programs are closely followed. Cash runway and competition in oral obesity drugs are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward GPCR’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
31Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
Net income growth from the prior fiscal year to the latest.
Free cash flow yield is free cash flow divided by market value: the cash a business generates for each dollar of its price.
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
26 weighted scorers; 13 had no data today and are left out rather than counted as zero.
Technical · daily
18Pulling it up
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
- RSI (14)99
Relative Strength Index (14-period) measures momentum by comparing recent gains to losses.
Williams %R (28-period) places the close within the last 28 periods' high-low range.
Holding it back
S&P 500 52-week comparison evaluates the stock's annual performance relative to the broader market.
Where the price sits between its 52-week low and high.
Performance versus SPY compares the stock's returns to the S&P 500 index.
61 weighted scorers; 4 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 52
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 31 | 1 |
| Daily | 18 | 3 |
| Weekly | 17 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 29 |
| Nov 18, 2026 | 29 |
| Nov 17, 2026 | 29 |
| Nov 16, 2026 | 29 |
| Nov 15, 2026 | 30 |
| Nov 14, 2026 | 30 |
| Nov 13, 2026 | 30 |
| Nov 12, 2026 | 28 |
| Nov 11, 2026 | 33 |
| Nov 10, 2026 | 34 |
| Nov 8, 2026 | 32 |
| Nov 7, 2026 | 32 |
| Nov 6, 2026 | 32 |
| Nov 5, 2026 | 30 |
| Nov 4, 2026 | 32 |
| Nov 3, 2026 | 31 |
| Nov 2, 2026 | 32 |
| Nov 1, 2026 | 34 |
| Oct 31, 2026 | 34 |
| Oct 30, 2026 | 33 |
| Oct 29, 2026 | 34 |
| Oct 28, 2026 | 32 |
| Oct 27, 2026 | 33 |
| Oct 26, 2026 | 32 |
| Oct 25, 2026 | 33 |
| Oct 24, 2026 | 33 |
| Oct 23, 2026 | 31 |
| Oct 22, 2026 | 33 |
| Oct 21, 2026 | 34 |
| Oct 20, 2026 | 35 |
| Oct 19, 2026 | 34 |
| Oct 18, 2026 | 33 |
| Oct 17, 2026 | 33 |
| Oct 16, 2026 | 32 |
| Oct 15, 2026 | 33 |
| Oct 14, 2026 | 32 |
| Oct 13, 2026 | 32 |
| Oct 12, 2026 | 32 |
| Oct 11, 2026 | 33 |
| Oct 10, 2026 | 33 |
| Oct 9, 2026 | 33 |
| Oct 8, 2026 | 33 |
| Oct 7, 2026 | 34 |
| Oct 6, 2026 | 34 |
| Oct 5, 2026 | 34 |
| Oct 4, 2026 | 33 |
| Oct 3, 2026 | 32 |
| Oct 2, 2026 | 33 |
| Oct 1, 2026 | 34 |
| Sep 30, 2026 | 34 |
| Sep 29, 2026 | 35 |
| Sep 28, 2026 | 37 |
| Sep 27, 2026 | 38 |
| Sep 26, 2026 | 38 |
| Sep 25, 2026 | 39 |
| Sep 24, 2026 | 39 |
| Sep 23, 2026 | 38 |
| Sep 22, 2026 | 39 |
| Sep 21, 2026 | 39 |
| Sep 20, 2026 | 37 |
| Sep 19, 2026 | 37 |
| Sep 18, 2026 | 37 |
| Sep 17, 2026 | 37 |
| Sep 16, 2026 | 35 |
| Sep 15, 2026 | 39 |
| Sep 14, 2026 | 38 |
| Sep 13, 2026 | 38 |
| Sep 12, 2026 | 38 |
| Sep 11, 2026 | 38 |
| Sep 10, 2026 | 38 |
| Sep 9, 2026 | 40 |
| Sep 8, 2026 | 41 |
| Sep 7, 2026 | 45 |
| Sep 6, 2026 | 45 |
| Sep 5, 2026 | 45 |
| Sep 4, 2026 | 44 |
| Sep 3, 2026 | 44 |
| Sep 2, 2026 | 46 |
| Sep 1, 2026 | 46 |
| Aug 31, 2026 | 41 |
| Aug 30, 2026 | 44 |
| Aug 29, 2026 | 44 |
| Aug 28, 2026 | 43 |
| Aug 27, 2026 | 46 |
| Aug 26, 2026 | 46 |
| Aug 25, 2026 | 47 |
| Aug 24, 2026 | 44 |
| Aug 23, 2026 | 45 |
| Aug 22, 2026 | 44 |
Key facts
- Market cap
- $1.2B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- -1.20
- Risk grade (1–10)
- —
- Next earnings
- Nov 9, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| GHRS GH Research | $1.3B | 42 |
| NVAX Novavax | $1.3B | 55 |
| MNKD MannKind | $1.3B | 56 |
| MLYS Mineralys Therapeutics | $1.3B | 31 |
| SLN Silence Therapeutics | $1.2B | 55 |
| TSHA Taysha Gene Therapies | $1.2B | 47 |
Questions
What is GPCR's stock rating today?
GPCR scores 29/100 (Bearish) as of Nov 19, 2026: technical 20, fundamental 31, and news sentiment 52, which is shown but not counted. Scores are recomputed every night.
What does Structure Therapeutics do?
Structure Therapeutics (GPCR) is a clinical-stage biopharmaceutical company that designs oral small-molecule drugs aimed at G-protein-coupled receptors, a large family of drug targets. It uses structural biology and computational chemistry to design pills that act on receptors usually targeted by injected peptide drugs.
Is GPCR stock a buy?
The score is not a buy or sell recommendation. A 29 says the technical and fundamental signals we measure lean bearish today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the GPCR score calculated?
87 weighted scorers feed it today: 26 fundamental, scored against Healthcare ranges, and 61 technical on the daily chart, with 3 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/gpcr/"><img src="https://stocksscores.com/stocks/gpcr/badge.svg" alt="GPCR stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/gpcr/)